Etoricoxib
Tier C — Watch / tradeEtoricoxib
Targets：COX-2
Brand：Arcoxia, Nucoxia, Tauxib
Indications (approved)：Osteoarthritis, 痛风性关节炎, Dysmenorrhoea, Rheumatoid arthritis, Ankylosing spondylitis
Regional status
Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ETOR-001 | 1072-98-6 | 5-chloropyridin-2-amine |
| ETOR-002 | 26163-03-1 | 3-bromo-5-chloropyridin-2-amine |
| ETOR-003 | 98546-51-1 | (4-(methylthio)phenyl)boronic acid |
| ETOR-004 | 217090-19-2 | 5-chloro-3-(4-(methylthio)phenyl)pyridin-2-amine |
| ETOR-005 | 202409-80-1 | 5-chloro-3-(4-(methylsulfonyl)phenyl)pyridin-2-amine |
| ETOR-006 | 202409-86-7 | 2,5-dichloro-3-(4-(methylsulfonyl)phenyl)pyridine |
| ETOR-007 | 217175-17-2 | Borate(1-), triethoxy(6-methyl-3-pyridinyl)-, lithium, (T-4)- (9CI) |
| Code | CAS No. | Intermediate |
|---|---|---|
| ETOR-008 | 5470-70-2 | methyl 6-methylnicotinate |
| ETOR-009 | 221615-71-0 | N-methoxy-N,6-dimethylnicotinamide |
| ETOR-010 | 53014-84-9 | 6-methylnicotinaldehyde |
| ETOR-011 | 307531-87-9 | diphenyl ((6-methylpyridin-3-yl)(phenylamino)methyl)phosphonate |
| ETOR-012 | 5398-77-6 | 4-(methylsulfonyl)benzaldehyde |
| ETOR-013 | - | (E)-N-(1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)aniline |
| ETOR-014 | 221615-75-4 | 1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethan-1-one |
| ETOR-015 | 291756-76-8 | - |
| ETOR-016 | - | (Z)-4-chloro-3,5-bis(dimethylamino)-1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)pent-4-en-1-one |
| ETOR-017 | - | (2Z,4Z)-4-chloro-5-(dimethylamino)-1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)penta-2,4-dien-1-one |
| Code | CAS No. | Intermediate |
|---|---|---|
| ETOR-009 | 221615-71-0 | N-methoxy-N,6-dimethylnicotinamide |
| ETOR-014 | 221615-75-4 | 1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethan-1-one |
| ETOR-019 | 874-87-3 | (4-(chloromethyl)phenyl)(methyl)sulfane |
| ETOR-020 | 221615-72-1 | 1-(6-methylpyridin-3-yl)-2-(4-(methylthio)phenyl)ethan-1-one |
| ETOR-021 | 50704-42-2 | (Z)-2-chloro-3-hydroxyacrylaldehyde |
| Code | CAS No. | Intermediate |
|---|---|---|
| ETOR-014 | 221615-75-4 | 1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethan-1-one |
| ETOR-022 | 1620210-75-4 | methyl (E)-2-chloro-3-(tosyloxy)acrylate |
| ETOR-023 | 1620210-76-5 | 3-chloro-6-(6-methylpyridin-3-yl)-5-(4-(methylsulfonyl)phenyl)-2H-pyran-2-one |
| ETOR-024 | - | 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-6-ol |
| ETOR-025 | 1620210-78-7 | 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-6-yl 4-methylbenzenesulfonate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ETOR-014 | 221615-75-4 | 1-(6-methylpyridin-3-yl)-2-(4-(methylsulfonyl)phenyl)ethan-1-one |
| ETOR-021 | 50704-42-2 | (Z)-2-chloro-3-hydroxyacrylaldehyde |
Frequently asked questions
What are the approved indications of Etoricoxib?
Approved indications include: Osteoarthritis, 痛风性关节炎, Dysmenorrhoea, Rheumatoid arthritis, Ankylosing spondylitis.
When does the Etoricoxib patent expire?
No public expiry year is available for Etoricoxib yet; this page updates once verified.
How many synthesis routes are recorded for Etoricoxib?
5 synthesis routes are recorded; the shortest is 1 steps with 1.81 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Etoricoxib intermediates?
All intermediates in Etoricoxib routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Etoricoxib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29